top_10_image_2

Top Ten most popular articles on Pharmafile.com this week

pharmafile | October 2, 2020 | News story | Medical Communications  

The top ten news stories this week focus on vaccines and treatments, with allegations Russia is sowing disinformation about COVID-19 vaccines to undermine inoculation efforts in Western aligned countries, according to a top UK military official, while GlaxoSmithKline has confirmed a new vaccine supply deal to deliver 300 million doses of its candidate to the European Commission.

In other news, the FDA has approved Pfizer’s Xeljanz (tofacitinib) for the treatment of children and adolescents with active polyarticular course juvenile idiopathic arthritis (pcJIA), while a Maryland federal judge denied Roche’s motion to throw out a lawsuit that alleges the company defrauded the US and state governments through misrepresenting Tamiflu’s benefit in combating the flu.

1. Novel prophylactic nasal spray reduced COVID-19 replication by 96% in animal studies

Australian biotech Ena Respiratory has revealed new data demonstrating that its novel nasal spray almost halted replication of the SARS-CoV-2 in animals when used as a prophylactic, showing potential to improve immune response when used alongside COVID-19 vaccines.

2. Russia is spreading lies about COVID-19 vaccines, alleges UK Chief of Defence Staff

Russia is sowing disinformation about COVID-19 vaccines to undermine inoculation efforts in Western aligned countries, according to a top UK military official.

3. Enlivex’s Allocetra improves COVID-19 recovery times, early data show

Israeli immunotherapy firm Enlivex Therapeutics has released tentatively positive data for its therapy Allocetra as a treatment for patients with severe and critical forms of COVID-19.

4. Judge allows $1.5 billion Tamiflu stockpiling lawsuit against Roche to go ahead

A Maryland federal judge denied Roche’s motion to throw out a lawsuit that alleges the company defrauded the US and state governments through misrepresenting Tamiflu’s benefit in combating the flu.

5. Company veteran Belén Garijo named as Merck KGaA’s first-ever female CEO

German pharma firm Merck KGaA has taken the decision to appoint its first female Chief Executive Officer in its 352-year history, promoting company veteran Belén Garijoto the position. She will commence her new role in May 2021, when current CEO Stefan Oschmann will step down from his responsibilities as previously planned.

6. GSK confirms deal to supply 300 million COVID-19 vaccine doses to the EU

GlaxoSmithKline has confirmed a new COVID-19 vaccine supply deal to deliver 300 million doses of its candidate to the European Commission.

7. Coronavirus transmission in India driven by superspreaders

India’s largest contract tracing study has found that the virus has been transmitted through ‘super spreaders.’

8. Pfizer’s Xeljanz approved by the FDA for the treatment of children with arthritis

The FDA has approved Pfizer’s Xeljanz (tofacitinib) for the treatment of children and adolescents with active polyarticular course juvenile idiopathic arthritis (pcJIA).

9. NICE gives go-ahead for Sandoz’s Rizmoic to treat opioid-induced constipation

The National Institute for Health and Care Excellence (NICE) has recommended Sandoz’s Rizmoic (naldemedine) for the treatment of opioid-induced constipation (OIC) in adults who have already received laxative treatment, meaning the therapy can now be used in routine use on the NHS in England and Wales.

10. Novartis unveils strong Phase 3 efficacy for one-time therapy Zolgensma in paediatric spinal muscular atrophy

Novartis has lifted the curtain on new Phase 3 data from an ongoing trial of 33 participants on the efficacy of its one-time intravenous infusion of Zolgensma (onasemnogene abeparvovec) in the treatment of spinal muscular atrophy (SMA) Type 1 in paediatric patients.

Related Content

No items found

Latest content